Home » Stocks » INVA

Innoviva, Inc. (INVA)

Stock Price: $10.56 USD -0.23 (-2.13%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $10.49 -0.07 (-0.66%) Nov 25, 4:36 PM

Stock Price Chart

Key Info

Market Cap 1.07B
Revenue (ttm) 322.29M
Net Income (ttm) 216.45M
Shares Out 101.39M
EPS (ttm) 1.91
PE Ratio 5.53
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $10.56
Previous Close $10.79
Change ($) -0.23
Change (%) -2.13%
Day's Open 10.73
Day's Range 10.48 - 10.78
Day's Volume 378,302
52-Week Range 7.58 - 15.62

More Stats

Market Cap 1.07B
Enterprise Value 974.86M
Earnings Date (est) Feb 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 101.39M
Float 68.98M
EPS (basic) 2.14
EPS (diluted) 1.91
FCF / Share 2.91
Dividend n/a
Dividend Yield n/a
Earnings Yield 18.09%
FCF Yield 27.53%
Payout Ratio n/a
Shares Short 10.08M
Short Ratio 13.16
Short % of Float 14.61%
Beta 0.65
PE Ratio 5.53
Forward PE n/a
P/FCF Ratio 3.63
PS Ratio 3.32
PB Ratio 2.33
Revenue 322.29M
Operating Income 309.98M
Net Income 216.45M
Free Cash Flow 294.71M
Net Cash 95.84M
Net Cash / Share 0.95
Gross Margin 80.99%
Operating Margin 96.18%
Profit Margin 67.20%
FCF Margin 91.44%
ROA 24.24%
ROE 67.59%
ROIC 35.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Sell

Price Target

Current: $10.56
Target: 10.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth0%20.16%62.63%147.58%539.74%86.08%-19.26%-77.1%1.19%-
Gross Profit26126121713453.958.434.535.6124.5124.22
Operating Income24623818410931.58-33.93-28.80-25.15-110-78.32
Net Income15739513459.54-18.76-168-171-18.54-115-83.86
Shares Outstanding10110110711011511210290.9182.0572.07
Earnings Per Share1.433.531.170.53-0.16-1.50-1.67-0.20-1.41-1.16
EPS Growth-59.49%201.71%120.75%-------
Dividend Per Share----0.756.10----
Dividend Growth-----87.7%-----
Operating Cash Flow25722414260.9810.13-131-130-128-88.34-75.14
Capital Expenditures-0.01---0.28-0.01-0.69-2.73-2.59-3.63-0.85
Free Cash Flow25722414260.7110.12-131-132-130-91.97-75.99
Cash & Equivalents351115129150187240466249242311
Total Debt377383599716733726288173173173
Net Cash / Debt-26.28-268-470-566-546-48517876.8269.34138
Book Value313154-243-353-343-223299155-87.05-22.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Innoviva, Inc.
Country United States
Employees 5
CEO Pavel Raifeld

Stock Information

Ticker Symbol INVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INVA
IPO Date October 5, 2004


Innoviva engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.